Qureight, a Cambridge-based health tech company, has raised £15 million in a Series B funding round [1]. The funding will help the firm as it looks to scale its AI-powered clinical trial imaging platform.
The company has developed a digital infrastructure and 3D deep learning platform for curating, analysing and extracting precision endpoints from complex scans of lungs and hearts.
With the new injection of capital, the company will construct a specialised AI imaging laboratory to house its 3D chest imaging foundation model, enabling it it to rapidly construct new predictive model.
The funding will also help the company as it seeks to expand its scope. While currently focused on lung fibrosis, Quereight is seeking to expand into adjacent therapeutic areas, such as pulmonary hypertension, bronchiectasis, asthma and drug-induced lung toxicity.
Major biopharma partners, including AstraZeneca and Vicore Pharma, already use Qureight’s platform to accelerate decision-making and integrate synthetic control arms, in addition to streamlining global site onboarding for clinical trials.
The Series B round was led by Molten Ventures, with participation from existing backers XTX Ventures, Hargreave Hale AIM VCT, Meltwind, Ascension and Guinness Ventures.
Dr Muhunthan Thillai, who co-founded Qureight with radiologist Alessandro Ruggiero, commented: “Expanding our 3D imaging deep learning models with our new AI laboratory will complement our existing dominance in lung fibrosis, allow us to enter new markets, and solidify our leadership position in the lung and heart imaging CRO market.”
Dr Inga Deakin, a partner at Molten Ventures, added: “Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research. The team’s rapid deployment of solutions in areas of unmet need underscores their unique capability to drive the next generation of medical innovation.”
[1]: Qureight closes £15m round to scale AI imaging platform